ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.
Journal of Clinical Oncology
◽
10.1200/jco.2011.29.15_suppl.575
◽
2011
◽
Vol 29
(15_suppl)
◽
pp. 575-575
◽
Cited By ~ 1
Author(s):
I. Lang
◽
R. Bell
◽
F. Feng
◽
R. I. Lopez
◽
J. Jassem
◽
...
Keyword(s):
Breast Cancer
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Positive Breast Cancer
Download Full-text
Related Documents
Cited By
References
Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
PharmacoEconomics
◽
10.1007/s40273-018-0634-5
◽
2018
◽
Vol 36
(4)
◽
pp. 505-505
Author(s):
Amir Ansaripour
◽
Carin A. Uyl-de Groot
◽
W. Ken Redekop
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Scenario Analysis
◽
Treatment Strategy
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Optimal Treatment Strategy
◽
Positive Breast Cancer
Download Full-text
Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy – current evidence and future trends
Expert Opinion on Investigational Drugs
◽
10.1517/13543781003730135
◽
2010
◽
Vol 19
(sup1)
◽
pp. S31-S39
◽
Cited By ~ 4
Author(s):
Otto Metzger-Filho
◽
Tushar Vora
◽
Ahmad Awada
Keyword(s):
Breast Cancer
◽
Cancer Progression
◽
Breast Cancer Progression
◽
Current Evidence
◽
Future Trends
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Positive Breast Cancer
Download Full-text
Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”
PharmacoEconomics
◽
10.1007/s40273-018-0621-x
◽
2018
◽
Vol 36
(3)
◽
pp. 383-384
Author(s):
Noga Gershon
◽
Yakir Berchenko
Keyword(s):
Breast Cancer
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Positive Breast Cancer
Download Full-text
Adjuvant Trastuzumab Therapy In Her2-Positive Breast Cancer Patients: A Meta-Analysis Of Published Randomized Trials
Value in Health
◽
10.1016/j.jval.2013.03.622
◽
2013
◽
Vol 16
(3)
◽
pp. A128
Author(s):
Y. Xia
◽
B. Bian
◽
E. Costea
◽
C.M. Kelton
◽
J.J. Guo
Keyword(s):
Breast Cancer
◽
Cancer Patients
◽
Randomized Trials
◽
Meta Analysis
◽
Breast Cancer Patients
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Positive Breast Cancer
Download Full-text
PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
Value in Health
◽
10.1016/j.jval.2011.02.916
◽
2011
◽
Vol 14
(3)
◽
pp. A165
Author(s):
T.T.T. Nguyen
◽
R. Yagudina
◽
A.U. Kulikov
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Early Stage
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Positive Breast Cancer
Download Full-text
Cost-Effectiveness Analysis of 1-Year Adjuvant Trastuzumab Therapy of Early-Stage Her2-Positive Breast Cancer
Value in Health
◽
10.1016/j.jval.2014.08.107
◽
2014
◽
Vol 17
(7)
◽
pp. A735
◽
Cited By ~ 1
Author(s):
Nguyen TTC
◽
Nguyen TTT
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Early Stage
◽
Cost Effectiveness Analysis
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Effectiveness Analysis
◽
Positive Breast Cancer
Download Full-text
Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’
PharmacoEconomics
◽
10.1007/s40273-018-0620-y
◽
2018
◽
Vol 36
(3)
◽
pp. 381-382
Author(s):
Amir Ansaripour
◽
Carin A. Uyl-de Groot
◽
W. Ken Redekop
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Scenario Analysis
◽
Treatment Strategy
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Optimal Treatment Strategy
◽
Positive Breast Cancer
Download Full-text
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
PharmacoEconomics
◽
10.1007/s40273-017-0557-6
◽
2017
◽
Vol 36
(1)
◽
pp. 91-103
◽
Cited By ~ 11
Author(s):
Amir Ansaripour
◽
Carin A. Uyl-de Groot
◽
W. Ken Redekop
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Scenario Analysis
◽
Treatment Strategy
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Optimal Treatment Strategy
◽
Positive Breast Cancer
Download Full-text
Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer
Clinical Breast Cancer
◽
10.3816/cbc.2008.n.037
◽
2008
◽
Vol 8
(4)
◽
pp. 324-333
◽
Cited By ~ 48
Author(s):
Mohammad Jahanzeb
Keyword(s):
Breast Cancer
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Positive Breast Cancer
Download Full-text
Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718043513.793482079
◽
2013
◽
Author(s):
Ana Maria Gonzalez-Angulo
Keyword(s):
Breast Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Her2 Positive
◽
Open Label
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Randomised Controlled
◽
Positive Breast Cancer
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close